1976 Long term rotation trials

Long term rotation trials - W56H, 66M29, 67C13, 67N4, 68E5, 68SG5, 69GE20, 73SG16, Soil fertility - grain lupins - 75TS23

1975 Soil fertility - grain lupins - long term rotation trials

Soil Fertility - Grain Lupins 75A4, 75BA6, 75E4, 75GE9, 75JE9, 75MT6, 75N028, 75WH9. Long Term. Rotation Trials W56H, 66M29, 67Cl3, 67N4, 68E5, 68SG5, 69GE20, 73SG16. Soil Fertility - Grain Lupins Use of the stage 4 lupin variety trials to assess the effect of a year of sweet grain lupins on a following cereal crop was continued. The 1974 variety trials contained a number of lupin varieties randomised with two standard wheat varieties. Also at two times of planting. Eight trials were selected: 74GE26 at Morawa, 74BA7 at Badgingarra, 74WH8 at Wongan Hills, 74N08 at Bolgart, 74A8 at Beverley, 74MT8 at Mount Barker, 74JE9 at Gairdner River, 74E8 at Gibson. The 1974 plots in these trials were sown to Gamenya wheat in 1975 (except for 74MT8, Swan oats used to prevent take-all complication). - 75GE9, 75A4, 75BA6, 75E4, 75GE9, 75JE9, 75MT6, 75N028, 75WH9

Long Term Rotation Trials

The object of these trials is to attempt to determine the best rotation for each area or at least give some guidelines for recommendations as to the optimum rotation. Also to determine the effect of various pasture phases on the performance of the following crops and the number of crops required to utilise any accrued benefit from the pasture. In addition the trials on the Salmon Gums Research Station (68SG5) will attempt to compare cereal rotations on both volunteer and barrel medic pastures. It is also hoped to be able to get some estimate of grazing production from barrel medic and volunteer pastures. The trial being run by the Geraldton District Office at Northampton (68GE8) will determine the best rotation for soil badly infected with cereal eelworm. Also find the effect of various lengths of pasture and fallow on the level of eelworm in the soil. The eelworm work is being carried out by Miss Goss of Plant Pathology

Long term rotation trials - Annual summary of results 1975

Long term rotation trials: Results are the yield of grain harvested from crops grown after various lengths of pasture ley. W56H, 66M29, 67C13, 67N4, 68SG5

1973 Long term rotation trials

The results shown are the yield of grain harvested from crops grown after various lengths of pasture ley. Experiments - W56H, 66M29, 67BA6, 68E5, 68SG5, 69GE20

1973 Long term rotation trials - summary of results

The results shown are the yield of grain harvested from crops grown after various lengths of pasture ley. W56H, 66M29, 67BA6, 68E5, 68SG5, 69GE20

Transformative action coaching in healthcare leadership

The context of this study focuses on the collaborative interest of three organizations devoted to the development of Healthcare leadership in the United Kingdom, namely the National Health Service (NHS), Army Medical Service (AMS), and the University of Cumbria (UoC). Each organization acknowledges the challenges facing healthcare leaders in their pursuit of effect organizational, personal, and professional learning and have come together and bring into play their own organizational learning to collectively design this pilot programme of leadership development that facilitates deep transformative critical self- reflection, reflexivity and learning. The authors have used the theoretical and practical integration of autoethnographic storytelling and arts-based action learning approaches to facilitate such transformative learning in the group setting of professional leadership development programmes. The aim of this study is to add to the growing discourses in the fields of Transformative Learning, Action Learning, Coaching and Autoethnography by critically evaluating the application of this approach when designing and delivering a combined military, university and NHS leadership development program to a cohort of 24 senior leaders within an NHS hospital

Assessing the in vivo data on low/no-calorie sweeteners and the gut microbiota

Low/no-calorie sweeteners (LNCS) are continually under the spotlight in terms of their safety and benefits; in 2014 a study was published linking LNCS to an enhanced risk of glucose intolerance through modulation of the gut microbiota. In response, an in-depth review of the literature was undertaken to evaluate the major contributors to potential changes in the gut microbiota and their corresponding sequelae, and to determine if consuming LNCS (e.g., acesulfame K, aspartame, cyclamate, neotame, saccharin, sucralose, steviol glycosides) contributes to changes in the microbiome based on the data reported in human and animal studies. A few rodent studies with saccharin have reported changes in the gut microbiome, but primarily at high doses that bear no relevance to human consumption. This and other studies suggesting an effect of LNCS on the gut microbiota were found to show no evidence of an actual adverse effect on human health. The sum of the data provides clear evidence that changes in the diet unrelated to LNCS consumption are likely the major determinants of change in gut microbiota numbers and phyla, confirming the viewpoint supported by all the major international food safety and health regulatory authorities that LNCS are safe at currently approved levels

The anti-proliferative Effects of enterolactone in prostate cancer cells: evidence for the role of DNA licencing genes, mi-R106b cluster expression, and PTEN dosage

The mammalian lignan, enterolactone, has been shown to reduce the proliferation of the earlier stages of prostate cancer at physiological concentrations in vitro. However, efficacy in the later stages of the disease occurs at concentrations difficult to achieve through dietary modification. We have therefore investigated what concentration(s) of enterolactone can restrict proliferation in multiple stages of prostate cancer using an in vitro model system of prostate disease. We determined that enterolactone at 20 μM significantly restricted the proliferation of mid and late stage models of prostate disease. These effects were strongly associated with changes in the expression of the DNA licencing genes (GMNN, CDT1, MCM2 and 7), in reduced expression of the miR-106b cluster (miR-106b, miR-93, and miR-25), and in increased expression of the PTEN tumour suppressor gene. We have shown anti-proliferative effects of enterolactone in earlier stages of prostate disease than previously reported and that these effects are mediated, in part, by microRNA-mediated regulation